Developer docs
API playgroundTry for free, no card

Search company profiles

Cellipont Bioservices

Full company profile

uuid00065ji

Namestring
Cellipont Bioservices
Legal namestring
Cellipont Bioservices
Websiteurl
cellipont.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Cellipont Bioservices is a privately held cell therapy Contract Development and Manufacturing Organization (CDMO) founded in 2006 and headquartered in The Woodlands, Texas. The company provides process development, analytical development, technology transfer, and cGMP clinical and commercial manufacturing services for autologous and allogeneic cell therapies — including CAR-T, iPSC-derived therapies, exosomes, mesenchymal stem cells (MSCs), macrophage, dendritic cell, and TCR-T programs — to clinical-stage biotechnology and pharmaceutical clients. Cellipont operates a 76,000 sq. ft. purpose-built manufacturing facility with 7 clean rooms, QC labs, temperature-controlled storage, and — as of December 2025 — a ballroom-style cleanroom equipped with a 50-liter single-use bioreactor for large-scale allogeneic production. Its technology stack integrates the ADVA X3 automated cell therapy manufacturing platform (the first North American CDMO deployment), the L7|ESP unified Manufacturing Execution System from L7 Informatics, and the Xiogenix Ares X20 fill-finish system.

The company's commercial model is B2B fee-for-service CDMO engagement: project-based, quote-negotiated contracts with biotech and pharma sponsors. Revenue is generated through development services, technology transfer projects, and clinical and commercial manufacturing campaigns. Cellipont sells through a dedicated enterprise commercial team (Chief Commercial Officer Edwin Beale, with VP and Senior Director of Business Development) targeting clinical-stage cell therapy developers, supported by industry conference participation (ASGCT, ISCT, BIO, MESA), PR, LinkedIn, and the corporate website. The company is majority-owned by Great Point Partners (GPP), with a minority growth equity investment from HealthQuest Capital (October 2024) and prior strategic debt financing from OrbiMed (2023). The named customer base spans at least 12 clinical-stage biotechs (Marker Therapeutics, Wugen, Secretome Therapeutics, Diakonos Oncology, Ernexa Therapeutics, Optieum Biotechnologies, BobcatBio, Mongoose Bio, Soter Bio, Applied StemCell, Ronawk, CellVax Therapeutics), with most engagements at Phase I clinical manufacturing stage and a 2026 collaboration extending Cellipont's scope into GMP RNA biomolecule manufacturing.

Short descriptiontext

Cellipont Bioservices is a privately held, B2B cell therapy CDMO founded in 2006 and headquartered in The Woodlands, Texas, providing cGMP process development and manufacturing services for autologous and allogeneic cell therapies to clinical-stage biotech and pharmaceutical clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersThe Woodlands, United States
HQ citystring
The Woodlands
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy CDMO, contract manufacturing services, cGMP cell manufacturing, cell therapy development, process development services
Industry3 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Cellipont operates as a Contract Development and Manufacturing Organization (CDMO) providing fee-for-service development and manufacturing to biotech/pharma clients. Revenue generated through project-based contracts for process development, analytical services, technology transfer, and cGMP manufacturing of cell therapies.

cellipont.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cellipont Bioservices is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides fee-for-service process development, analytical development, technology transfer, and cGMP manufacturing of cell therapies including CAR-T, allogeneic, autologous, iPSC-derived therapies, and exosomes. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas with seven cleanrooms, integrated QC labs, and advanced closed processing systems, serving biotech and pharmaceutical clients from early process development through commercial manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Cell and gene therapy manufacturing market projected to reach USD 146.2 billion by 2032
+1 more record
Product overview1 text field

Cellipont Bioservices is a premier cell therapy Contract Development and Manufacturing Organization (CDMO) offering a comprehensive suite of manufacturing services. The company's service portfolio includes CAR-T Services, Allogeneic Cell Therapy, Autologous Cell Therapy, iPSC Services, and Exosome Manufacturing. These services are supported by integrated capabilities spanning Process Development & Analytical Development, Clinical Manufacturing, Quality Control, and Quality & Compliance. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas featuring 7 clean rooms, QC labs, and advanced closed processing systems. Cellipont also offers technology access partnerships including the ADVA X3® automated manufacturing platform and Xiogenix Ares™ X20 fill-finish system.

Product and service9 records
1CAR-T Services
CategoryCell Therapy CDMO Service
Description

Comprehensive CAR-T cell therapy development and manufacturing services for biotech and pharmaceutical clients, spanning process development through commercial manufacturing of chimeric antigen receptor T-cell therapies.

2Allogeneic Cell Therapy
CategoryCell Therapy CDMO Service
Description

Development and manufacturing services for allogeneic (off-the-shelf) cell therapies derived from healthy donor cells, supporting biotech and pharmaceutical clients with large-scale commercial production capabilities.

3Autologous Cell Therapy
CategoryCell Therapy CDMO Service
Description

Personalized autologous cell therapy manufacturing services using a patient's own cells, providing cGMP manufacturing for biotech and pharmaceutical clients developing patient-specific cell therapies.

4iPSC Services
CategoryCell Therapy CDMO Service
Description

Induced pluripotent stem cell (iPSC) development and manufacturing services for cell therapy applications, supporting biotech and pharmaceutical clients developing iPSC-derived therapies.

5Exosome Manufacturing
CategoryCell Therapy CDMO Service
Description

cGMP exosome manufacturing services for therapeutic applications, providing biotech and pharmaceutical clients with scalable production of exosome-based therapeutics.

6Process Development and Analytical Development
CategoryCell Therapy CDMO Capability
Description

Comprehensive process development and analytical method development services for cell therapy manufacturing, enabling clients to optimize production processes and establish analytical methods for cell therapy products.

7Clinical Manufacturing
CategoryCell Therapy CDMO Capability
Description

cGMP clinical manufacturing services supporting biotech and pharmaceutical clients through early to late-stage clinical trial supply of cell therapy products at the purpose-built The Woodlands, Texas facility.

8Quality Control
CategoryCell Therapy CDMO Capability
Description

Quality control testing services for cell therapy products, ensuring safety, purity, and potency of client products through integrated QC labs at the cGMP manufacturing facility.

9Quality and Compliance
CategoryCell Therapy CDMO Capability
Description

Regulatory compliance and quality assurance services meeting global GMP standards for cell therapy manufacturing clients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Strategic collaboration to provide integrated iPSC-derived cell therapy development services, combining ASC's GMP iPSC lines and TARGATT gene editing technology with Cellipont's cGMP manufacturing and regulatory expertise. Aims to reduce technical risk and shorten development timelines by connecting upstream cell engineering with late-stage manufacturing.

2BobcatBio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

Strategic collaboration to advance macrophage-based cell therapy RB-1355 for solid tumors. Cellipont will perform Phase I cell product manufacturing in support of BobcatBio's ongoing solid tumor and lymphoma clinical trials.

cellipont.com
3Soter Bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Strategic collaboration for integrated U.S. cell therapy and RNA biomolecule manufacturing. Cellipont provides GMP cell therapy manufacturing and regulatory support while Soter Bio supplies GMP RNA and biomolecule manufacturing capabilities. Aims to accelerate development timelines and strengthen domestic manufacturing resilience.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Strategic partnership to accelerate scalable expansion of high-quality mesenchymal stem cells (MSCs). Combines Cellipont's cGMP manufacturing expertise with Ronawk's Bio-OS platform to address industry challenges in scalability, consistency, and cost-effectiveness for MSC-based therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

Manufacturing partnership to advance ERNA-101 cell therapy for ovarian cancer into clinical trials. Focuses on manufacturing process development supporting clinical trial preparations for Ernexa's synthetic allogeneic stem cell therapy platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Collaboration for cGMP manufacturing of MT-601 multi-antigen recognizing T cell therapy for patients with lymphoma. Cellipont provides technology transfer and cGMP manufacturing to support scale-up and production for Marker Therapeutics' APOLLO study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Partnership for cGMP manufacturing of OPTF01, Optieum's novel CAR-T therapy for glioblastoma treatment derived from their proprietary Eumbody System. Cellipont provides technology transfer, process development, and cGMP manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-22
Description

Partnership for cGMP manufacturing of Master Cell Bank for STM-01, a novel cell therapy derived from neonatal cardiac progenitor cells for treatment of heart failure. Cellipont provides technology transfer, analytical method transfer, and cGMP manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

Agreement for Technology Transfer, Process Development, and cGMP Manufacture of MGB-001, Mongoose Bio's autologous TCR-T cell therapy program targeting solid tumors. Built on 17 years of pioneering work by founder Dr. Cassian Yee at MD Anderson.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-05-07
Description

Partnership marking the launch of ADVA X3 platform in North America. ADVA X3 is an advanced, fully automated manufacturing platform for CAR-T and other cell therapies, streamlining processes and reducing costs. Cellipont is first CDMO in North America to offer this platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-14
Description

Agreement for clinical manufacture of Wugen's allogeneic, off-the-shelf CAR-T cell therapies for treatment of hematological and solid tumor malignancies. Cellipont provides technology transfer and production at their purpose-built facility.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-17
Description

Strategic partnership deploying L7 Informatics' L7|ESP unified platform and MES application to digitalize cell therapy manufacturing recipes, streamline technology transfers, and enable end-to-end manufacturing operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-10
Description

Agreement for Process Development and cGMP Manufacturing of DOC1021, an autologous dendritic cell vaccine for treatment of glioblastoma multiforme and other cancer indications. Diakonos received FDA Fast Track designation for this therapy.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cell and gene therapy CDMO offering process development, viral vector, plasmid and cell therapy GMP manufacturing. Comparable emerging cell-therapy CDMO competing for clinical-stage biotech outsourcing.

TypeBroad incumbent
Description

Major global cell and gene therapy CDMO offering autologous and allogeneic cell therapy process development and GMP manufacturing. A larger incumbent with overlapping service lines; however, increasing U.S. BIOSECURE-related restrictions on WuXi materially limit their U.S. market access, which is a non-trivial tailwind for Cellipont.

TypeDirect peer
Description

Cell and gene therapy CDMO operating BaseCamp, a centralized process development and GMP manufacturing hub for cell therapies, viral vectors and gene editing. Similar end-to-end service model targeting the same clinical-stage biotech customer set.

TypeBroad incumbent
Description

Large-scale CDMO actively expanding into cell therapy and gene therapy manufacturing alongside its biologics core. A broader incumbent that overlaps with Cellipont in cell therapy services but competes from a much larger, diversified portfolio.

TypeDirect peer
Description

The most direct competitor: a cell and gene therapy CDMO offering allogeneic and autologous CAR-T manufacturing services. Cellipont's CEO, COO and CCO all previously held senior roles here, underscoring head-to-head competition for the same biotech programs.

TypeDirect peer
Description

Cell therapy CDMO offering process development, analytical and GMP manufacturing services for autologous and allogeneic cell therapies including CAR-T and iPSC. Closely comparable niche cell-therapy CDMO model.

TypeDirect peer
Description

Global CDMO with dedicated cell and gene therapy manufacturing services, offering autologous and allogeneic cell therapy process development and GMP manufacturing. Cellipont's COO (O'Mara) and VP of Program Management (Kuzniar) both came from Lonza, indicating direct talent and customer overlap.

TypeDirect peer
Description

Purpose-built cell and gene therapy CDMO offering process development, viral vector, cell therapy and plasmid manufacturing from a single King of Prussia facility. Closely comparable scale, footprint and offering mix to Cellipont's Texas facility.

9Charles River Laboratories (Cell Therapy CDMO)
TypeDirect peer
Description

Provides cell therapy process development, viral vector and GMP manufacturing services to biotech and pharma clients. Operates comparable cell therapy CDMO services and competes for the same clinical-stage cell therapy outsourcing contracts.

TypeDirect peer
Description

Global CDMO with cell therapy, viral vector and plasmid manufacturing capabilities serving biotech developers. Competes directly with Cellipont for autologous and allogeneic cell therapy CDMO engagements.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellipont Bioservices

Cell Therapy CDMO Servicescellipont.com

Cellipont Bioservices is a privately held, B2B cell therapy CDMO founded in 2006 and headquartered in The Woodlands, Texas, providing cGMP process development and manufacturing services for autologous and allogeneic cell therapies to clinical-stage biotech and pharmaceutical clients.

What Cellipont Bioservices does

Cellipont Bioservices is a privately held cell therapy Contract Development and Manufacturing Organization (CDMO) founded in 2006 and headquartered in The Woodlands, Texas. The company provides process development, analytical development, technology transfer, and cGMP clinical and commercial manufacturing services for autologous and allogeneic cell therapies — including CAR-T, iPSC-derived therapies, exosomes, mesenchymal stem cells (MSCs), macrophage, dendritic cell, and TCR-T programs — to clinical-stage biotechnology and pharmaceutical clients. Cellipont operates a 76,000 sq. ft. purpose-built manufacturing facility with 7 clean rooms, QC labs, temperature-controlled storage, and — as of December 2025 — a ballroom-style cleanroom equipped with a 50-liter single-use bioreactor for large-scale allogeneic production. Its technology stack integrates the ADVA X3 automated cell therapy manufacturing platform (the first North American CDMO deployment), the L7|ESP unified Manufacturing Execution System from L7 Informatics, and the Xiogenix Ares X20 fill-finish system.

The company's commercial model is B2B fee-for-service CDMO engagement: project-based, quote-negotiated contracts with biotech and pharma sponsors. Revenue is generated through development services, technology transfer projects, and clinical and commercial manufacturing campaigns. Cellipont sells through a dedicated enterprise commercial team (Chief Commercial Officer Edwin Beale, with VP and Senior Director of Business Development) targeting clinical-stage cell therapy developers, supported by industry conference participation (ASGCT, ISCT, BIO, MESA), PR, LinkedIn, and the corporate website. The company is majority-owned by Great Point Partners (GPP), with a minority growth equity investment from HealthQuest Capital (October 2024) and prior strategic debt financing from OrbiMed (2023). The named customer base spans at least 12 clinical-stage biotechs (Marker Therapeutics, Wugen, Secretome Therapeutics, Diakonos Oncology, Ernexa Therapeutics, Optieum Biotechnologies, BobcatBio, Mongoose Bio, Soter Bio, Applied StemCell, Ronawk, CellVax Therapeutics), with most engagements at Phase I clinical manufacturing stage and a 2026 collaboration extending Cellipont's scope into GMP RNA biomolecule manufacturing.

Cellipont Bioservices firmographics

Firmographics
Name
Cellipont Bioservices
Legal name
Cellipont Bioservices
Website
https://cellipont.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Cellipont Bioservices is a privately held, B2B cell therapy CDMO founded in 2006 and headquartered in The Woodlands, Texas, providing cGMP process development and manufacturing services for autologous and allogeneic cell therapies to clinical-stage biotech and pharmaceutical clients.
Ownership category
akta.pro rank

Cellipont Bioservices industry classification

Industry
Product category
Cell Therapy CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy CDMO
  • Contract manufacturing services
  • CGMP cell manufacturing
  • Cell therapy development
  • Process development services

Where Cellipont Bioservices is headquartered

Location

Headquarters

HQ city
The Woodlands
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cellipont Bioservices business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Cellipont operates as a Contract Development and Manufacturing Organization (CDMO) providing fee-for-service development and manufacturing to biotech/pharma clients. Revenue generated through project-based contracts for process development, analytical services, technology transfer, and cGMP manufacturing of cell therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cellipont Bioservices product offering

Product offering

Core offering

Cellipont Bioservices is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides fee-for-service process development, analytical development, technology transfer, and cGMP manufacturing of cell therapies including CAR-T, allogeneic, autologous, iPSC-derived therapies, and exosomes. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas with seven cleanrooms, integrated QC labs, and advanced closed processing systems, serving biotech and pharmaceutical clients from early process development through commercial manufacturing.

Product overview

Cellipont Bioservices is a premier cell therapy Contract Development and Manufacturing Organization (CDMO) offering a comprehensive suite of manufacturing services. The company's service portfolio includes CAR-T Services, Allogeneic Cell Therapy, Autologous Cell Therapy, iPSC Services, and Exosome Manufacturing. These services are supported by integrated capabilities spanning Process Development & Analytical Development, Clinical Manufacturing, Quality Control, and Quality & Compliance. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas featuring 7 clean rooms, QC labs, and advanced closed processing systems. Cellipont also offers technology access partnerships including the ADVA X3® automated manufacturing platform and Xiogenix Ares™ X20 fill-finish system.

Differentiator

Problem solved

Functional benefit

Products and services

  • CAR-T Services Comprehensive CAR-T cell therapy development and manufacturing services for biotech and pharmaceutical clients, spanning process development through commercial manufacturing of chimeric antigen receptor T-cell therapies.
  • Allogeneic Cell Therapy Development and manufacturing services for allogeneic (off-the-shelf) cell therapies derived from healthy donor cells, supporting biotech and pharmaceutical clients with large-scale commercial production capabilities.
  • Autologous Cell Therapy Personalized autologous cell therapy manufacturing services using a patient's own cells, providing cGMP manufacturing for biotech and pharmaceutical clients developing patient-specific cell therapies.
  • iPSC Services Induced pluripotent stem cell (iPSC) development and manufacturing services for cell therapy applications, supporting biotech and pharmaceutical clients developing iPSC-derived therapies.
  • Exosome Manufacturing cGMP exosome manufacturing services for therapeutic applications, providing biotech and pharmaceutical clients with scalable production of exosome-based therapeutics.
  • Process Development and Analytical Development Comprehensive process development and analytical method development services for cell therapy manufacturing, enabling clients to optimize production processes and establish analytical methods for cell therapy products.
  • Clinical Manufacturing cGMP clinical manufacturing services supporting biotech and pharmaceutical clients through early to late-stage clinical trial supply of cell therapy products at the purpose-built The Woodlands, Texas facility.
  • Quality Control Quality control testing services for cell therapy products, ensuring safety, purity, and potency of client products through integrated QC labs at the cGMP manufacturing facility.
  • Quality and Compliance Regulatory compliance and quality assurance services meeting global GMP standards for cell therapy manufacturing clients.

Quantifiable outcome

  • Cell and gene therapy manufacturing market projected to reach USD 146.2 billion by 2032
  • +1 more outcomes

Companies that use Cellipont Bioservices

Customer profile

Named customers12 records

Segments1 record

Ideal customer profiles1 record

Cellipont Bioservices technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Cellipont Bioservices partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core.

  • Applied StemCellcoreStrategic or Co-development Partner · 24 March 2026Strategic collaboration to provide integrated iPSC-derived cell therapy development services, combining ASC's GMP iPSC lines and TARGATT gene editing technology with Cellipont's cGMP manufacturing and regulatory expertise. Aims to reduce technical risk and shorten development timelines by connecting upstream cell engineering with late-stage manufacturing.
  • BobcatBiocoreStrategic or Co-development Partner · 16 March 2026Strategic collaboration to advance macrophage-based cell therapy RB-1355 for solid tumors. Cellipont will perform Phase I cell product manufacturing in support of BobcatBio's ongoing solid tumor and lymphoma clinical trials.
  • Soter BiocoreStrategic or Co-development Partner · 24 February 2026Strategic collaboration for integrated U.S. cell therapy and RNA biomolecule manufacturing. Cellipont provides GMP cell therapy manufacturing and regulatory support while Soter Bio supplies GMP RNA and biomolecule manufacturing capabilities. Aims to accelerate development timelines and strengthen domestic manufacturing resilience.
  • RonawkcoreStrategic or Co-development Partner · 19 November 2025Strategic partnership to accelerate scalable expansion of high-quality mesenchymal stem cells (MSCs). Combines Cellipont's cGMP manufacturing expertise with Ronawk's Bio-OS platform to address industry challenges in scalability, consistency, and cost-effectiveness for MSC-based therapies.
  • Ernexa TherapeuticscoreStrategic or Co-development Partner · 29 October 2025Manufacturing partnership to advance ERNA-101 cell therapy for ovarian cancer into clinical trials. Focuses on manufacturing process development supporting clinical trial preparations for Ernexa's synthetic allogeneic stem cell therapy platform.
  • Marker TherapeuticscoreStrategic or Co-development Partner · 17 June 2025Collaboration for cGMP manufacturing of MT-601 multi-antigen recognizing T cell therapy for patients with lymphoma. Cellipont provides technology transfer and cGMP manufacturing to support scale-up and production for Marker Therapeutics' APOLLO study.
  • Optieum BiotechnologiescoreStrategic or Co-development Partner · 8 May 2025Partnership for cGMP manufacturing of OPTF01, Optieum's novel CAR-T therapy for glioblastoma treatment derived from their proprietary Eumbody System. Cellipont provides technology transfer, process development, and cGMP manufacturing.
  • Secretome TherapeuticscoreStrategic or Co-development Partner · 22 January 2025Partnership for cGMP manufacturing of Master Cell Bank for STM-01, a novel cell therapy derived from neonatal cardiac progenitor cells for treatment of heart failure. Cellipont provides technology transfer, analytical method transfer, and cGMP manufacturing.
  • Mongoose BiocoreStrategic or Co-development Partner · 8 October 2024Agreement for Technology Transfer, Process Development, and cGMP Manufacture of MGB-001, Mongoose Bio's autologous TCR-T cell therapy program targeting solid tumors. Built on 17 years of pioneering work by founder Dr. Cassian Yee at MD Anderson.
  • ADVA BiotechnologycoreTechnology or Integration · 7 May 2024Partnership marking the launch of ADVA X3 platform in North America. ADVA X3 is an advanced, fully automated manufacturing platform for CAR-T and other cell therapies, streamlining processes and reducing costs. Cellipont is first CDMO in North America to offer this platform.
  • WugencoreStrategic or Co-development Partner · 14 March 2024Agreement for clinical manufacture of Wugen's allogeneic, off-the-shelf CAR-T cell therapies for treatment of hematological and solid tumor malignancies. Cellipont provides technology transfer and production at their purpose-built facility.
  • L7 InformaticscoreTechnology or Integration · 17 January 2024Strategic partnership deploying L7 Informatics' L7|ESP unified platform and MES application to digitalize cell therapy manufacturing recipes, streamline technology transfers, and enable end-to-end manufacturing operations.
  • Diakonos OncologycoreStrategic or Co-development Partner · 10 October 2023Agreement for Process Development and cGMP Manufacturing of DOC1021, an autologous dendritic cell vaccine for treatment of glioblastoma multiforme and other cancer indications. Diakonos received FDA Fast Track designation for this therapy.

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

Cellipont Bioservices competitors and assessment

Company assessment

Direct peers

  • Genezen: Cell and gene therapy CDMO offering process development, viral vector, plasmid and cell therapy GMP manufacturing. Comparable emerging cell-therapy CDMO competing for clinical-stage biotech outsourcing.
  • ElevateBio: Cell and gene therapy CDMO operating BaseCamp, a centralized process development and GMP manufacturing hub for cell therapies, viral vectors and gene editing. Similar end-to-end service model targeting the same clinical-stage biotech customer set.
  • Catalent Cell & Gene Therapy (formerly MaSTherCell): The most direct competitor: a cell and gene therapy CDMO offering allogeneic and autologous CAR-T manufacturing services. Cellipont's CEO, COO and CCO all previously held senior roles here, underscoring head-to-head competition for the same biotech programs.
  • BioCentriq: Cell therapy CDMO offering process development, analytical and GMP manufacturing services for autologous and allogeneic cell therapies including CAR-T and iPSC. Closely comparable niche cell-therapy CDMO model.
  • Lonza Cell & Gene Technologies: Global CDMO with dedicated cell and gene therapy manufacturing services, offering autologous and allogeneic cell therapy process development and GMP manufacturing. Cellipont's COO (O'Mara) and VP of Program Management (Kuzniar) both came from Lonza, indicating direct talent and customer overlap.
  • Center for Breakthrough Medicines (CBM): Purpose-built cell and gene therapy CDMO offering process development, viral vector, cell therapy and plasmid manufacturing from a single King of Prussia facility. Closely comparable scale, footprint and offering mix to Cellipont's Texas facility.
  • Charles River Laboratories (Cell Therapy CDMO): Provides cell therapy process development, viral vector and GMP manufacturing services to biotech and pharma clients. Operates comparable cell therapy CDMO services and competes for the same clinical-stage cell therapy outsourcing contracts.
  • AGC Biologics (Cell and Gene Therapy): Global CDMO with cell therapy, viral vector and plasmid manufacturing capabilities serving biotech developers. Competes directly with Cellipont for autologous and allogeneic cell therapy CDMO engagements.

Broad incumbents

  • WuXi Advanced Therapies Unit: Major global cell and gene therapy CDMO offering autologous and allogeneic cell therapy process development and GMP manufacturing. A larger incumbent with overlapping service lines; however, increasing U.S. BIOSECURE-related restrictions on WuXi materially limit their U.S. market access, which is a non-trivial tailwind for Cellipont.
  • FUJIFILM Diosynth Biotechnologies: Large-scale CDMO actively expanding into cell therapy and gene therapy manufacturing alongside its biologics core. A broader incumbent that overlaps with Cellipont in cell therapy services but competes from a much larger, diversified portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellipont Bioservices social profiles

Digital presence

Cellipont Bioservices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellipont Bioservices leadership team

Management profile

Number of profiles

Profiles8 records

Cellipont Bioservices funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellipont Bioservices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellipont Bioservices

What does Cellipont Bioservices do?

Cellipont Bioservices is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides fee-for-service process development, analytical development, technology transfer, and cGMP manufacturing of cell therapies including CAR-T, allogeneic, autologous, iPSC-derived therapies, and exosomes. The company operates a purpose-built 76,000 sq. ft. cGMP manufacturing facility in The Woodlands, Texas with seven cleanrooms, integrated QC labs, and advanced closed processing systems, serving biotech and pharmaceutical clients from early process development through commercial manufacturing.

Is Cellipont Bioservices a public or private company?

Cellipont Bioservices is a private company. It is classified as private equity controlled and is currently operating.

When was Cellipont Bioservices founded?

Cellipont Bioservices was founded in 2006. It employs 51 to 100 people.

Where is Cellipont Bioservices based?

Cellipont Bioservices is headquartered in The Woodlands, United States, in the North America region.

How does Cellipont Bioservices make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Cellipont Bioservices's main competitors?

Direct peers on record are Genezen, ElevateBio, Catalent Cell & Gene Therapy (formerly MaSTherCell), BioCentriq, Lonza Cell & Gene Technologies, Center for Breakthrough Medicines (CBM), Charles River Laboratories (Cell Therapy CDMO) and AGC Biologics (Cell and Gene Therapy). Broad incumbents are WuXi Advanced Therapies Unit and FUJIFILM Diosynth Biotechnologies.

Does Cellipont Bioservices have an API?

No public API is recorded for Cellipont Bioservices.

What industry is Cellipont Bioservices in?

Cellipont Bioservices's product category is Cell Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanMarker Therapeutics: Kincellis partner has 140,000 sq. ft.Marker Therapeutics highlighted expanded manufacturing support from its CDMO partner Kincellis, formed by combining Cellipont Bioservices and Kincell Bio. The combined CDMO has about 140,000 square feet of infrastructure and 16 GMP suites across three U.S. locations, strengthening MT-601 manufacturing as it advances toward later-stage trials.BioSpaceKincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced TherapiesKincell Bio and Cellipont Bioservices merged to form Kincellis Advanced Therapies, a U.S.-based CDMO for cell therapies. The combined company has released over 150 GMP batches and supports 10 IND filings this year. The merger was led by NewSpring Capital with support from existing investors and J.P. Morgan.CellipontKincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies. Combination creates a scaled U.S. advanced therapies CDMO with broader technical expertise and capabilities from earlyKincell Bio and Cellipont Bioservices merged to form Kincellis Advanced Therapies, a U.S. cell therapy CDMO. The combined company operates 140,000 square feet of facilities and has released over 150 GMP batches, supporting 10 IND filings this year. Equity financing was led by NewSpring Capital with support from existing investors.KincellbioKincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced TherapiesKincell Bio and Cellipont Bioservices merged to form Kincellis Advanced Therapies, a U.S. CDMO for cell therapies. The combined company operates 140,000 square feet across three sites and has released over 150 GMP batches, supporting 10 IND filings this year.BioSpaceCellipont Bioservices and Xiogenix Publish New White Paper on Automated Fill-Finish for Scalable Cell Therapy ManufacturingCellipont Bioservices and Xiogenix published a white paper on automated fill-finish for cell therapy manufacturing, evaluating Xiogenix's ARES X20+ platform. The study found consistent formulation performance across a 17-fold scale increase, with final volume accuracy of 98.2% at small scale and 103.6% at large scale, and stable cell viability. The findings aim to address scalability constraints as cell therapy programs advance.PR NewswireCellipont Bioservices and Xiogenix Publish New White Paper on Automated Fill-Finish for Scalable Cell Therapy ManufacturingCellipont Bioservices and Xiogenix published a white paper evaluating Xiogenix's ARES X20+ automated fill-finish platform for cell therapy manufacturing. The study found consistent formulation performance across a 17-fold scale increase, with final volume accuracy of 98.2% at small scale and 103.6% at large scale. The companies will discuss the findings at the CAR-TCR Summit in September.PR NewswireStem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen ResearchThe global stem cells market is projected to grow from USD 18.9 billion in 2026 to USD 32.57 billion by 2031, a CAGR of 11.5%, driven by regenerative medicine and cell-based therapies. Adult stem cells led product revenue in 2025, and North America held the largest regional share. Asia-Pacific is the fastest-growing region.PR NewswireCellipont Bioservices' Texas Facility Has Supported Six Client Projects Expected to Reach IND Submission in 2026Cellipont Bioservices announced its Texas facility has supported six client projects expected to reach Investigational New Drug application submission in 2026. The company's 76,000 sq. ft. purpose-built facility supports autologous and allogeneic cell therapy programs from early development through clinical manufacturing.AijournCellipont Bioservices Celebrates Release of 100th GMP BatchCellipont Bioservices, a cell therapy contract development and manufacturing organization, announced the successful release of its 100th GMP batch at its manufacturing facility in The Woodlands, Texas, approximately one year after initiating GMP manufacturing operations in June 2025. The milestone reflects the company's operational infrastructure, growing client demand, and cross-functional team dedication, according to CEO Darren Head. The company continues to expand its capabilities to support cell therapy developers from process development through clinical and commercial manufacturing.PR NewswireCellipont Bioservices Celebrates Release of 100th GMP BatchCellipont Bioservices announced the successful release of its 100th Good Manufacturing Practice (GMP) batch at its facility in The Woodlands, Texas. This milestone was achieved approximately one year after the company initiated GMP operations there in June 2025, highlighting strong operational infrastructure and growing client demand.